Ondine Biomedical Inc. Expands Steriwave Technology to New Healthcare Facilities

Ondine Biomedical Inc., a Canadian life sciences company, is marking significant strides in 2024 by expanding the deployment of its Steriwave® technology into eight new healthcare facilities, including six hospitals. This development augments the total to 22 hospitals employing Steriwave, a notable 38% increase year-to-date, showcasing nearly fourfold growth compared to the previous year. Additionally, Toronto area will soon host Steriwave in two orthopedic surgeon group practices for elective procedures.

The Ottawa Hospital is notably enhancing its Steriwave usage, previously successful in pilot spine surgeries, to now include surgeries in orthopedics and vascular fields. This expansion signifies Steriwave’s application in approximately 2,600 surgeries annually at TOH, marking a threefold increase. The growth in Steriwave's application underscores the healthcare sector's effort to mitigate avoidable costs amidst the rise in antibiotic resistance, with Steriwave proving to be a cost-effective solution in reducing post-surgical infections.

Ondine's recent commercial endeavors also span across paid adoptions of Steriwave in new territories including Spain and various healthcare facilities in Canada. Steriwave's efficacy and safety were further validated by the results presented at the SPIE Photonics West conference, confirming its benign impact on the nasal microbiome over extensive patient applications. Continuous discussions aim to further Steriwave's commercial reach, addressing the urgent need for effective infection prevention methods in healthcare settings.